Telitacicept reduced the 24-hour urine protein-to-creatinine ratio by 58.9% at Week 39, compared with an 8.8% reduction on placebo (p<0.0001) in Stage A of a Phase 3 IgA nephropathy study in China (n=318). Risk of a ≥30% eGFR decline was 6.3% on telitacicept versus 27.0% on placebo; 61.0%, 42.1%, and 24.5% of treated patients achieved UPCR thresholds of <0.8, <0.5, and <0.3 g/g, respectively, compared with 19.5%, 7.5%, and 0.6% on placebo. Serious adverse events occurred in 2.5% of telitacicept patients versus 8.2% on placebo, with overall TEAEs more frequent on telitacicept but predominantly mild or moderate. The core development: Vor Bio and collaborator RemeGen reported that the randomized, double-blind, placebo-controlled Phase 3 met its primary endpoint for proteinuria at 39 weeks, with statistically significant improvements across kidney function–related secondary endpoints and pharmacodynamic markers. The trial evaluated once-weekly subcutaneous telitacicept 240 mg versus placebo in adults with IgAN at high risk of progression on stable background therapy. RemeGen has submitted a BLA to China’s CDE for IgAN, positioning telitacicept for a potential fifth approved indication in China. The dataset was featured as a late-breaking oral at ASN Kidney Week 2025. Strategically, a China-first filing on a robust proteinuria signal underscores how rapidly the IgAN competitive field is moving to convert surrogate endpoints into market access while longer-term eGFR slope data mature. Dual BAFF/APRIL inhibition is one of the dominant B-cell–targeted strategies in IgAN, and these results will be parsed against emerging anti-APRIL and dual-pathway readouts for differences in proteinuria depth, eGFR durability, and immunosuppression burden. Weekly subcutaneous dosing and a clean SAE profile at 39 weeks add practical advantages in a category where efficacy is converging and safety management and operational simplicity increasingly shape adoption. The collaboration also signals an intent to leverage Chinese pivotal infrastructure and timelines as springboards for broader development, even as global regulatory standards may demand longer follow-up. For sites, the regimen implies predictable weekly visits or home health workflows, routine monitoring of immunoglobulins and B-cell counts, and standard renal endpoints—operationally tractable compared with steroid-based or multi-agent approaches. Sponsors and CROs will note the two-stage architecture typical in IgAN, anchoring near-term filings on proteinuria while accumulating eGFR slope; this design remains aligned with regional regulatory expectations but will need harmonization for U.S./EU submissions. Regulators are likely to focus on the durability of proteinuria remission across thresholds linked to prognosis, maintenance of eGFR stabilization beyond 39 weeks, and infection profiles as exposure lengthens. Vendors supporting decentralized sample collection and immunomonitoring stand to benefit if weekly SC administration drives more hybrid site models. Next, attention shifts to Stage B outcomes and the longer-term eGFR slope to validate the disease-modifying intent, as well as to clarify background therapy standards and subgroup consistency under contemporary care. If NMPA approval follows, watch uptake dynamics in China relative to existing steroidal and nonsteroidal options, and whether real-world infection and hypogammaglobulinemia rates track the trial’s safety signal. Globally, the key questions are whether telitacicept pursues bridging or independent trials in IgAN, how it will differentiate versus anti-APRIL antibodies and other pathways, and whether operational strengths—weekly SC, manageable monitoring—translate into faster site activation and broader patient reach. Competitive data flow over the next 12–18 months will determine if BAFF/APRIL dual blockade secures a durable class position or faces segmentation by mechanism, safety, and logistics.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
